PriceTargets.com logo

NASDAQ:INFI - Infinity Pharmaceuticals Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $9.00
  • Forecasted Upside: 202.01 %
  • Number of Analysts: 8
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 6 Buy Ratings
  • 0 Strong Buy Ratings
$2.98 As of 04/16/2021 01:00 AM ET
▼ -0.1 (-3.25%)
1 month | 3 months | 12 months
Get New Infinity Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for INFI and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for INFI

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$9.00
▲ +202.01% Upside Potential
This price target is based on 8 analysts offering 12 month price targets for Infinity Pharmaceuticals in the last 3 months. The average price target is $9.00, with a high forecast of $12.00 and a low forecast of $4.00. The average price target represents a 202.01% upside from the last price of $2.98.
Buy
The current consensus among 8 investment analysts is to buy stock in Infinity Pharmaceuticals. This rating has held steady since October 2019, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 1 sell ratings
Ratings as of
10/25/2019
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/23/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
4/22/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
7/21/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
10/19/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
1/17/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
3/18/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
4/17/2021

Latest Recommendations

  • 0 strong buy ratings
  • 6 buy ratings
  • 2 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/24/2021Truist SecuritiesInitiated CoverageBuy$12.00High
i
3/23/2021B. RileyLower Price TargetBuy$8.00 ➝ $7.00Low
i
3/23/2021Wells Fargo & CompanyBoost Price TargetEqual Weight$2.00 ➝ $4.00Low
i
3/18/2021Truist FinancialInitiated CoverageBuy$12.00High
i
3/18/2021Truist SecuritiesInitiated CoverageBuy$12.00High
i
3/18/2021TruistInitiated CoverageBuy$12.00High
i
3/17/2021Wells Fargo & CompanyBoost Price TargetEqual Weight$2.00 ➝ $4.00High
i
2/25/2021Piper SandlerInitiated CoverageOverweight$7.00Medium
i
2/18/2021Piper SandlerInitiated CoverageOverweight$7.00 ➝ $7.00Low
i
2/12/2021B. RileyBoost Price TargetBuy$4.50 ➝ $8.00Low
i
2/11/2021OppenheimerBoost Price TargetOutperform$5.50 ➝ $9.00Low
i
2/5/2021JPMorgan Chase & Co.UpgradeUnderweight ➝ NeutralMedium
i
12/11/2020B. RileyBoost Price TargetBuy$3.00 ➝ $4.50High
i
11/13/2020B. RileyBoost Price TargetBuy$2.50 ➝ $3.00High
i
7/31/2020OppenheimerReiterated RatingBuyHigh
i
Rating by Kevin DeGeeter at Oppenheimer Holdings Inc.
5/18/2020B. RileyLower Price TargetBuy$3.50 ➝ $2.50Low
i
Rating by G. Zavoico at B. Riley
5/12/2020Wells Fargo & CompanyLower Price TargetEqual Weight$1.50 ➝ $1.00High
i
5/11/2020OppenheimerReiterated RatingBuy$3.00High
i
3/4/2020Wells Fargo & CompanyLower Price TargetEqual Weight$2.50 ➝ $1.50Medium
i
11/18/2019B. RileyInitiated CoverageBuy$3.50High
i
Rating by Andrew D'silva at B. Riley
6/27/2019CIBCInitiated CoverageOutperform ➝ OutperformLow
i
6/27/2019OppenheimerInitiated CoverageOutperform$3.00Medium
i
1/7/2019UBS GroupReiterated RatingReduceHigh
i
1/4/2019B. RileyInitiated CoverageBuy ➝ Buy$3.00 ➝ $3.00High
i
Rating by G. Zavoico at B. Riley
11/12/2018Wells Fargo & CompanyDowngradeOutperform ➝ Market PerformHigh
i
11/12/2018JPMorgan Chase & Co.DowngradeNeutral ➝ UnderweightHigh
i
5/31/2018Seaport Global SecuritiesInitiated CoverageBuy$4.00Medium
i
Rating by C. Davis at Seaport Global Securities
10/12/2017Wells Fargo & CompanyUpgradeMarket Perform ➝ OutperformN/A
i
11/10/2016JPMorgan Chase & Co.Reiterated RatingHoldN/A
i
8/11/2016Morgan StanleyReiterated RatingHold$1.00N/A
i
Rating by Matthew Harrison at Morgan Stanley
8/10/2016(FBRC)Reiterated RatingHoldN/A
i
Rating by christopher james at (FBRC)
8/9/2016WedbushReiterated RatingNeutral$1.25 ➝ $1.00N/A
i
Rating by David Nierengarten at Wedbush
6/28/2016(FBRC)Reiterated RatingMarket Perform$2.00N/A
i
Rating by Christopher James at (FBRC)
6/28/2016WedbushReiterated RatingNeutral$1.25N/A
i
Rating by David Nierengarten at Wedbush
6/15/2016Jefferies Financial GroupDowngradeBuy ➝ HoldN/A
i
6/15/2016William BlairDowngradeOutperform ➝ Market Perform$20.00 ➝ $2.00N/A
i
Rating by Y. Xu at William Blair
6/15/2016Wells Fargo & CompanyDowngradeOutperform ➝ Market PerformN/A
i
6/15/2016Morgan StanleyDowngradeOverweight ➝ Equal WeightN/A
i
6/14/2016(FBRC)DowngradeOutperform ➝ Market Perform$15.00 ➝ $2.00N/A
i
Rating by Christopher James at (FBRC)
6/14/2016Royal Bank of CanadaDowngradeOutperform ➝ Sector Perform$12.00 ➝ $2.00N/A
i
Rating by Michael Yee at Royal Bank of Canada
6/14/2016JMP SecuritiesDowngradeOutperform ➝ Market PerformN/A
i
6/14/2016WedbushUpgradeUnderperform ➝ Neutral$3.00 ➝ $1.25N/A
i
Rating by David Nierengarten at Wedbush
6/14/2016JPMorgan Chase & Co.DowngradeOverweight ➝ NeutralN/A
i
Rating by Anupam Rama at JPMorgan Chase & Co.
6/13/2016(FBRC)DowngradeOutperform ➝ Market Perform$15.00 ➝ $2.00N/A
i
Rating by Christopher James at (FBRC)
5/10/2016(FBRC)Reiterated RatingBuyN/A
i
Rating by Christopher James at (FBRC)
5/5/2016WedbushReiterated RatingUnderperform$3.00N/A
i
Rating by David Nierengarten at Wedbush
4/28/2016(FBRC)Reiterated RatingBuyN/A
i
Rating by Christopher James at (FBRC)
(Data available from 4/17/2016 forward)
Infinity Pharmaceuticals logo
Infinity Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing novel medicines for people with cancer. It offers IPI-549, an orally administered, clinical-stage, immuno-oncology product candidate that selectively inhibits the enzyme phosphoinositide-3-kinase-gamma Its product candidate is IPI-549, an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma (PI3K-gamma), which is in Phase 1/1b clinical study. The company has strategic alliances with Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K; Verastem, Inc. to research, develop, commercialize, and manufacture duvelisib and products containing duvelisib, as well as duvelisib program for patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma; and PellePharm, Inc. to develop and commercialize rights to its hedgehog inhibitor program, IPI-926, a clinical-stage product candidate, as well as collaboration agreements with Arcus Biosciences, Inc., F. Hoffmann-La Roche Ltd., and Bristol-Myers Squibb Company. Infinity Pharmaceuticals, Inc. is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $2.98
$2.92
$3.07

50 Day Range

MA: $3.18
$2.60
$3.64

52 Week Range

Now: $2.98
$0.78
$5.98

Volume

871,493 shs

Average Volume

3,682,772 shs

Market Capitalization

$264.15 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.4

Frequently Asked Questions

What sell-side analysts currently cover shares of Infinity Pharmaceuticals?

The following equities research analysts have issued research reports on Infinity Pharmaceuticals in the last twelve months: B. Riley, JPMorgan Chase & Co., Oppenheimer Holdings Inc., Piper Sandler, Truist, Truist Financial Co., Truist Securities, Wells Fargo & Company, and Zacks Investment Research.
View the latest analyst ratings for INFI.

What is the current price target for Infinity Pharmaceuticals?

7 Wall Street analysts have set twelve-month price targets for Infinity Pharmaceuticals in the last year. Their average twelve-month price target is $9.00, suggesting a possible upside of 202.0%. Truist Financial Co. has the highest price target set, predicting INFI will reach $12.00 in the next twelve months. Wells Fargo & Company has the lowest price target set, forecasting a price of $4.00 for Infinity Pharmaceuticals in the next year.
View the latest price targets for INFI.

What is the current consensus analyst rating for Infinity Pharmaceuticals?

Infinity Pharmaceuticals currently has 2 hold ratings and 6 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe INFI will outperform the market and that investors should add to their positions of Infinity Pharmaceuticals.
View the latest ratings for INFI.

What other companies compete with Infinity Pharmaceuticals?

Other companies that are similar to Infinity Pharmaceuticals include Amgen, Gilead Sciences, Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Biogen, Alexion Pharmaceuticals, Seagen, Exact Sciences, Incyte, Novavax, Alnylam Pharmaceuticals, BioMarin Pharmaceutical, Repligen, Neurocrine Biosciences and United Therapeutics.

How do I contact Infinity Pharmaceuticals' investor relations team?

Infinity Pharmaceuticals' physical mailing address is 1100 MASSACHUSETTS AVENUE FLOOR 4, CAMBRIDGE MA, 02138. The biotechnology company's listed phone number is 617-453-1000 and its investor relations email address is [email protected] The official website for Infinity Pharmaceuticals is www.infi.com.